Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expec ...

Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 -- SLS009: Full Topline Phase 2 Data ...

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...

Introduction: Progressing myelodysplastic syndrome (MDS) into acute myeloid leukemia (AML) is an indication for hypomethylating therapy (HMA, 5-Azacytidine (AZA)) and a BCL2 inhibitor (Venetoclax, VEN ...

Clonal hematopoiesis of indeterminate potential (CHIP) has been associated with an increased risk of cardiovascular (CV) disease, which could reflect the interaction between mutant CHIP clones, immune ...

1 Qilu Hospital, Cheeloo College of Medicine, Shandong University, Qingdao, Shandong, China 2 Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, ...

Two abstracts presented at the 2024 American Society of Hematology Annual Meeting & Exhibition provided insight into MDS ...